Ann: Change of CFO and Company Secretary, page-3

It may help some to read this announcement in detail. It was more about company performance according to me.

“The Company has a strong finance team, a solid balance sheetwith record cash levels and robust underlying liquidity and is confident in the future with three attractive business segments (specialty brands, generics and contract services) that continue to be in demand during this unprecedented time. In addition, the Company has many near term opportunities to create shareholder value including the planned launch of generic NUVARING® this calendar year and the commercialisation of novel oral contraceptive E4/DRSP in the first half of calendar 2021. The Company continues to generate free cash flow across the second half of FY20 and is tightly managing capital expenditure, R&D spend and operating expenses.”